Logo image of DIM.PA

SARTORIUS STEDIM BIOTECH (DIM.PA) Stock Fundamental Analysis

EPA:DIM - Euronext Paris - Matif - FR0013154002 - Common Stock - Currency: EUR

201.9  +7.4 (+3.8%)

Fundamental Rating

4

Taking everything into account, DIM scores 4 out of 10 in our fundamental rating. DIM was compared to 15 industry peers in the Life Sciences Tools & Services industry. DIM has an average financial health and profitability rating. DIM is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

5

1. Profitability

1.1 Basic Checks

In the past year DIM was profitable.
In the past year DIM had a positive cash flow from operations.
Each year in the past 5 years DIM has been profitable.
In the past 5 years DIM always reported a positive cash flow from operatings.
DIM.PA Yearly Net Income VS EBIT VS OCF VS FCFDIM.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

1.2 Ratios

With a Return On Assets value of 2.12%, DIM perfoms like the industry average, outperforming 46.67% of the companies in the same industry.
DIM's Return On Equity of 4.38% is in line compared to the rest of the industry. DIM outperforms 46.67% of its industry peers.
Looking at the Return On Invested Capital, with a value of 4.03%, DIM is doing worse than 66.67% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for DIM is above the industry average of 6.90%.
The last Return On Invested Capital (4.03%) for DIM is well below the 3 year average (10.41%), which needs to be investigated, but indicates that DIM had better years and this may not be a problem.
Industry RankSector Rank
ROA 2.12%
ROE 4.38%
ROIC 4.03%
ROA(3y)7.81%
ROA(5y)9.13%
ROE(3y)17.3%
ROE(5y)20.06%
ROIC(3y)10.41%
ROIC(5y)14.57%
DIM.PA Yearly ROA, ROE, ROICDIM.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30

1.3 Margins

With a decent Profit Margin value of 6.29%, DIM is doing good in the industry, outperforming 73.33% of the companies in the same industry.
In the last couple of years the Profit Margin of DIM has declined.
DIM has a Operating Margin (13.32%) which is comparable to the rest of the industry.
In the last couple of years the Operating Margin of DIM has declined.
DIM has a Gross Margin (43.40%) which is in line with its industry peers.
DIM's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 13.32%
PM (TTM) 6.29%
GM 43.4%
OM growth 3Y-22.38%
OM growth 5Y-9.98%
PM growth 3Y-24.01%
PM growth 5Y-17.3%
GM growth 3Y-6.9%
GM growth 5Y-3.53%
DIM.PA Yearly Profit, Operating, Gross MarginsDIM.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40 50

More info and screens

4

2. Health

2.1 Basic Checks

DIM has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
DIM has more shares outstanding than it did 1 year ago.
The number of shares outstanding for DIM has been increased compared to 5 years ago.
The debt/assets ratio for DIM has been reduced compared to a year ago.
DIM.PA Yearly Shares OutstandingDIM.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
DIM.PA Yearly Total Debt VS Total AssetsDIM.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

2.2 Solvency

An Altman-Z score of 3.93 indicates that DIM is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.93, DIM is in the better half of the industry, outperforming 80.00% of the companies in the same industry.
The Debt to FCF ratio of DIM is 6.04, which is on the high side as it means it would take DIM, 6.04 years of fcf income to pay off all of its debts.
DIM has a worse Debt to FCF ratio (6.04) than 60.00% of its industry peers.
DIM has a Debt/Equity ratio of 0.70. This is a neutral value indicating DIM is somewhat dependend on debt financing.
The Debt to Equity ratio of DIM (0.70) is worse than 73.33% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.7
Debt/FCF 6.04
Altman-Z 3.93
ROIC/WACC0.51
WACC7.88%
DIM.PA Yearly LT Debt VS Equity VS FCFDIM.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.3 Liquidity

A Current Ratio of 1.85 indicates that DIM should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.85, DIM is in the better half of the industry, outperforming 80.00% of the companies in the same industry.
A Quick Ratio of 1.12 indicates that DIM should not have too much problems paying its short term obligations.
The Quick ratio of DIM (1.12) is better than 66.67% of its industry peers.
Industry RankSector Rank
Current Ratio 1.85
Quick Ratio 1.12
DIM.PA Yearly Current Assets VS Current LiabilitesDIM.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 4.97% over the past year.
The Earnings Per Share has been growing slightly by 4.19% on average over the past years.
DIM shows a small growth in Revenue. In the last year, the Revenue has grown by 0.16%.
Measured over the past years, DIM shows a quite strong growth in Revenue. The Revenue has been growing by 14.05% on average per year.
EPS 1Y (TTM)4.97%
EPS 3Y-22.3%
EPS 5Y4.19%
EPS Q2Q%34.88%
Revenue 1Y (TTM)0.16%
Revenue growth 3Y-1.25%
Revenue growth 5Y14.05%
Sales Q2Q%11.65%

3.2 Future

Based on estimates for the next years, DIM will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.34% on average per year.
The Revenue is expected to grow by 9.61% on average over the next years. This is quite good.
EPS Next Y23.98%
EPS Next 2Y25.51%
EPS Next 3Y24.81%
EPS Next 5Y19.34%
Revenue Next Year9.64%
Revenue Next 2Y10.58%
Revenue Next 3Y10.89%
Revenue Next 5Y9.61%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
DIM.PA Yearly Revenue VS EstimatesDIM.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2B 4B 6B
DIM.PA Yearly EPS VS EstimatesDIM.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2 4 6 8 10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 53.13, which means the current valuation is very expensive for DIM.
Compared to the rest of the industry, the Price/Earnings ratio of DIM indicates a slightly more expensive valuation: DIM is more expensive than 73.33% of the companies listed in the same industry.
DIM's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 28.33.
Based on the Price/Forward Earnings ratio of 36.62, the valuation of DIM can be described as expensive.
Based on the Price/Forward Earnings ratio, DIM is valued a bit more expensive than the industry average as 66.67% of the companies are valued more cheaply.
When comparing the Price/Forward Earnings ratio of DIM to the average of the S&P500 Index (21.37), we can say DIM is valued expensively.
Industry RankSector Rank
PE 53.13
Fwd PE 36.62
DIM.PA Price Earnings VS Forward Price EarningsDIM.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of DIM indicates a rather expensive valuation: DIM more expensive than 80.00% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, DIM is valued a bit more expensive than 66.67% of the companies in the same industry.
Industry RankSector Rank
P/FCF 41.34
EV/EBITDA 31.4
DIM.PA Per share dataDIM.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30 40

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as DIM's earnings are expected to grow with 24.81% in the coming years.
PEG (NY)2.22
PEG (5Y)12.67
EPS Next 2Y25.51%
EPS Next 3Y24.81%

More info and screens

3

5. Dividend

5.1 Amount

With a yearly dividend of 0.37%, DIM is not a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 0.92, DIM is paying slightly less dividend.
Compared to an average S&P500 Dividend Yield of 2.51, DIM's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.37%

5.2 History

The dividend of DIM has a limited annual growth rate of 4.44%.
Dividend Growth(5Y)4.44%
Div Incr Years2
Div Non Decr Years2
DIM.PA Yearly Dividends per shareDIM.PA Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 2025 0.5 1

5.3 Sustainability

DIM pays out 38.39% of its income as dividend. This is a sustainable payout ratio.
DIM's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP38.39%
EPS Next 2Y25.51%
EPS Next 3Y24.81%
DIM.PA Yearly Income VS Free CF VS DividendDIM.PA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M
DIM.PA Dividend Payout.DIM.PA Dividend Payout, showing the Payout Ratio.DIM.PA Dividend Payout.PayoutRetained Earnings

More info and screens

SARTORIUS STEDIM BIOTECH

EPA:DIM (4/23/2025, 5:29:58 PM)

201.9

+7.4 (+3.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)04-16 2025-04-16/bmo
Earnings (Next)07-22 2025-07-22
Inst Owners11.63%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap19.65B
Analysts76.67
Price Target256.65 (27.12%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.37%
Yearly Dividend0.71
Dividend Growth(5Y)4.44%
DP38.39%
Div Incr Years2
Div Non Decr Years2
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.01%
Min EPS beat(2)-5.62%
Max EPS beat(2)7.63%
EPS beat(4)1
Avg EPS beat(4)-6.92%
Min EPS beat(4)-20.27%
Max EPS beat(4)7.63%
EPS beat(8)1
Avg EPS beat(8)-19.76%
EPS beat(12)1
Avg EPS beat(12)-20.47%
EPS beat(16)5
Avg EPS beat(16)-12.49%
Revenue beat(2)1
Avg Revenue beat(2)-1.1%
Min Revenue beat(2)-5.11%
Max Revenue beat(2)2.91%
Revenue beat(4)2
Avg Revenue beat(4)-2.22%
Min Revenue beat(4)-8.16%
Max Revenue beat(4)2.91%
Revenue beat(8)3
Avg Revenue beat(8)-1.91%
Revenue beat(12)4
Avg Revenue beat(12)-1.2%
Revenue beat(16)8
Avg Revenue beat(16)12.76%
PT rev (1m)-0.27%
PT rev (3m)15.32%
EPS NQ rev (1m)2.58%
EPS NQ rev (3m)16.05%
EPS NY rev (1m)-0.03%
EPS NY rev (3m)-0.27%
Revenue NQ rev (1m)-0.27%
Revenue NQ rev (3m)0.35%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.49%
Valuation
Industry RankSector Rank
PE 53.13
Fwd PE 36.62
P/S 7.07
P/FCF 41.34
P/OCF 24.11
P/B 4.93
P/tB N/A
EV/EBITDA 31.4
EPS(TTM)3.8
EY1.88%
EPS(NY)5.51
Fwd EY2.73%
FCF(TTM)4.88
FCFY2.42%
OCF(TTM)8.37
OCFY4.15%
SpS28.56
BVpS40.96
TBVpS-5.68
PEG (NY)2.22
PEG (5Y)12.67
Profitability
Industry RankSector Rank
ROA 2.12%
ROE 4.38%
ROCE 5.06%
ROIC 4.03%
ROICexc 4.45%
ROICexgc 14.12%
OM 13.32%
PM (TTM) 6.29%
GM 43.4%
FCFM 17.1%
ROA(3y)7.81%
ROA(5y)9.13%
ROE(3y)17.3%
ROE(5y)20.06%
ROIC(3y)10.41%
ROIC(5y)14.57%
ROICexc(3y)10.84%
ROICexc(5y)15.37%
ROICexgc(3y)26.31%
ROICexgc(5y)36.49%
ROCE(3y)13.07%
ROCE(5y)18.3%
ROICexcg growth 3Y-36.77%
ROICexcg growth 5Y-16.49%
ROICexc growth 3Y-43.34%
ROICexc growth 5Y-25.09%
OM growth 3Y-22.38%
OM growth 5Y-9.98%
PM growth 3Y-24.01%
PM growth 5Y-17.3%
GM growth 3Y-6.9%
GM growth 5Y-3.53%
F-Score5
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0.7
Debt/FCF 6.04
Debt/EBITDA 4.17
Cap/Depr 112.63%
Cap/Sales 12.22%
Interest Coverage 2.09
Cash Conversion 121.31%
Profit Quality 271.91%
Current Ratio 1.85
Quick Ratio 1.12
Altman-Z 3.93
F-Score5
WACC7.88%
ROIC/WACC0.51
Cap/Depr(3y)182.98%
Cap/Depr(5y)186.68%
Cap/Sales(3y)13.87%
Cap/Sales(5y)12.23%
Profit Quality(3y)126.76%
Profit Quality(5y)109.63%
High Growth Momentum
Growth
EPS 1Y (TTM)4.97%
EPS 3Y-22.3%
EPS 5Y4.19%
EPS Q2Q%34.88%
EPS Next Y23.98%
EPS Next 2Y25.51%
EPS Next 3Y24.81%
EPS Next 5Y19.34%
Revenue 1Y (TTM)0.16%
Revenue growth 3Y-1.25%
Revenue growth 5Y14.05%
Sales Q2Q%11.65%
Revenue Next Year9.64%
Revenue Next 2Y10.58%
Revenue Next 3Y10.89%
Revenue Next 5Y9.61%
EBIT growth 1Y-17.48%
EBIT growth 3Y-23.35%
EBIT growth 5Y2.67%
EBIT Next Year85.65%
EBIT Next 3Y36.02%
EBIT Next 5Y24.38%
FCF growth 1Y74.23%
FCF growth 3Y7.94%
FCF growth 5Y22.24%
OCF growth 1Y9.2%
OCF growth 3Y5.11%
OCF growth 5Y21.32%